=Inovio Pharmaceuticals (INO)

For an"Executive Decision" segment, Cramer sat down with Dr. Joseph Kim, president and CEO of Inovio Pharmaceuticals (INO) , a small biotech developing DNA-based immunotherapies to treat cancer. Shares of Inovio were up by 10.8% today on news that the company just received FDA approval to commence with Phase III trials for VGX-3100, Inovio's cervical cancer treatment.

Kim said that Inovio has been hard at work refining its delivery device for VGX-3100 and is getting ready to place 400 patients into its Phase III trials. He said this is the first non-surgical option for certain types of cervical cancer and Inovio is very excited.

Overall, Kim said, he's very encouraged by the data they've received and they have a wonderful platform that could yield therapies for many types of cancer. If things go well, VGX-3100 could file for FDA approval by 2021.

Kim was also encouraged by Inovio's partnership with Regeneron Pharmaceuticals (REGN) , wherein the companies are combining their drugs into a single treatment.